Physician profile
Marcus L Black
NPI 1396700613
$922.24
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $16.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $97.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $88.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.18 | 2019 | |
| Pfizer INC. | $71.63 | 2019 | |
| Janssen Biotech, INC. | $68.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.65 | 2019 | |
| Amgen INC. | $53.03 | 2019 | |
| Exelixis INC. | $49.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.01 | 2019 | |
| Genzyme Corporation | $38.92 | 2019 | |
| Merck Sharp & Dohme LLC | $38.33 | 2019 | |
| Genentech USA, INC. | $37.73 | 2019 | |
| Rigel Pharmaceuticals, INC. | $35.27 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $34.45 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $32.43 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.70 | 2019 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Incyte Corporation | $16.68 | 2019 | |
| Array Biopharma INC | $14.57 | 2019 | |
| Lilly USA, LLC | $14.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.